Literature DB >> 15161013

CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines.

Zaishun Jin1, Norihiro Teramoto, Kazuhiko Hayashi, Yi-Xuan Liu, Guishun Jin, Takashi Oka, Kiyoshi Takahashi, Tadashi Yoshino, Tadaatsu Akagi.   

Abstract

Mantle cell lymphoma (MCL) is a CD5+ non-Hodgkin's B-cell lymphoma characterized by the infiltration of intermediate sized B-cells into the mantle zones. Interaction between CD40L and CD40 is important for B cell proliferation and differentiation. CD40L stimulation can induce both growth arrest and proliferation of B cell lines according to their differentiation state. Previous reports examining the effect of stimulation via the CD40 cascade on ex vivo MCL cells have provided conflicting results. In this study, two MCL lines, SP49 and SP53, were examined for response to CD40L and/or IL-10. Co-cultivation with CD40L-expressing mouse L cells reduced the BrdU incorporation of SP49 and SP53 cells by half to one-third, while BrdU incorporation of control cell lines, including Ramos, BJAB and BALL-1, was not affected or increased. Anti-CD40L antibody blocked the CD40L inhibition of SP49 cell proliferation in a dose-dependent manner in the range from 0 to 20 ng/ml. IL-10 did not affect MCL cell proliferation in the presence or absence of CD40L-expressing cells, while Ramos proliferation was promoted by CD40L and IL-10. These results suggested the possibility that CD40L may also inhibit MCL proliferation in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161013

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2.

Authors:  Weiguo Han; David A Jackson; Stephan J Matissek; Jason A Misurelli; Matthew S Neil; Brandon Sklavanitis; Nansalmaa Amarsaikhan; Sherine F Elsawa
Journal:  J Immunol       Date:  2017-05-01       Impact factor: 5.422

2.  CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.

Authors:  Hilka Rauert-Wunderlich; Martina Rudelius; Ingolf Berberich; Andreas Rosenwald
Journal:  Cell Death Dis       Date:  2018-01-24       Impact factor: 8.469

3.  Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.

Authors:  Lavanya Lokhande; Venera Kuci Emruli; Arne Kolstad; Martin Hutchings; Riikka Räty; Mats Jerkeman; Sara Ek
Journal:  BMC Cancer       Date:  2020-12-07       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.